Read by QxMD icon Read

American Heart Journal

Jennifer A Rymer, Lisa A Kaltenbach, Kevin J Anstrom, Gregg C Fonarow, Nathaniel Erskine, Eric D Peterson, Tracy Y Wang
BACKGROUND: Low health literacy is common in the United States and may affect outcomes after myocardial infarction (MI). How often hospitals screen for low health literacy is unknown. METHODS: We surveyed 122 hospitals in the TRANSLATE-ACS study and divided them into those that reported routinely (>75% of patients), selectively (1%-75%), or never (0%) screening MI patients for low health literacy prior to discharge. We performed logistic regression with random intercepts to compare 6-week and 6-month patient-reported medication adherence and multivariable Cox regression to compare 1-year major adverse cardiovascular events and all-cause readmission risks between hospital groups...
April 2018: American Heart Journal
Derek S Chew, Stephen B Wilton, Katherine Kavanagh, Danielle A Southern, Liong Eng Tan-Mesiatowsky, Derek V Exner
BACKGROUND: Left ventricular (LV) dysfunction may be sustained or aggravated during the convalescent months following an acute myocardial infarction (MI) and is difficult to predict. We sought to determine current practice patterns of LV ejection fraction (LVEF) reassessment during the months following MI and evaluate the predictors and clinical significance of LVEF change in a prospective post-MI patient cohort. METHODS: Patients with an acute MI between June 2010 and August 2014 were identified using the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry...
April 2018: American Heart Journal
C Michael Gibson, Tarek Nafee, Megan K Yee, Gerald Chi, Serge Korjian, Yazan Daaboul, Fahad AlKhalfan, Mathieu Kerneis, Samuel Z Goldhaber, Russel Hull, Adrian F Hernandez, Alexander T Cohen, Robert A Harrington
BACKGROUND: Approximately 15%-30% of patients in trials of medical thromboprophylaxis will have missing compression ultrasound (CUS) data. The goal of the present analysis was to perform analyses to minimize missing data. METHODS: The APEX trial randomized 7,513 acutely medically ill hospitalized patients to thromboprophylaxis with either betrixaban for 35-42 days or enoxaparin for 6-14 days. A modified intent-to-treat (mITT) analysis was performed and included all subjects administered study drug, irrespective of CUS performance, and an analysis of symptomatic events which do not require performance of a CUS (symptomatic deep vein thrombosis, nonfatal pulmonary embolism, and venous thromboembolism (VTE)-related mortality)...
April 2018: American Heart Journal
Wayne Batchelor, Vishal Dahya, Dan McGee, John Katopodis, William Dixon, James Campbell, Ashley Meredith, Patty Knap, Mathew Parkin, Thomas Noel
There exist limited data on the relative degree of acute injury and late healing of the radial artery after transradial artery (TRA) percutaneous coronary intervention (PCI) with a 7F sheathless guide catheter compared with a 6F sheath/guide combination. We used ultrahigh-resolution (55 MHz) vascular ultrasound to compare intimal-medial thickening (IMT) and early and late radial artery (RA) injury resulting from a sheathless 7F guide catheter versus a 6F sheath/guide combination for TRA-PCI. METHODS: Forty-one consecutive consenting patients undergoing elective nonemergent TRA-PCI at a single institution from June 2016 to December 2016 were included...
April 2018: American Heart Journal
Benjamin Z Galper, David E Beery, Gregory Leighton, Libbe L Englander
BACKGROUND: Although outcomes data on transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (Mitraclip) are available via the Transcatheter Valve Therapy (TVT) registry, dissemination of TVT data is often delayed. The Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) system collects postmarket outcomes data in public medical device reports. We used natural language processing to compare the event rates for TAVR and Mitraclip in the TVT registry and from MAUDE data...
April 2018: American Heart Journal
Menno V Huisman, Kenneth J Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J Dubner, Jonathan L Halperin, Chang Sheng Ma, Kristina Zint, Amelie Elsaesser, Shihai Lu, Dorothee B Bartels, Gregory Y H Lip
BACKGROUND AND PURPOSE: GLORIA-AF is a large, global, prospective registry program of newly diagnosed atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the effectiveness and safety of dabigatran etexilate over 2 years from routine clinical practice in nearly 3000 patients from GLORIA-AF who are newly diagnosed with non-valvular AF and at risk of stroke. METHODS: Consecutive enrollment into phase II of GLORIA-AF was initiated following approval of dabigatran for stroke prevention in non-valvular AF...
April 2018: American Heart Journal
Tim Kinnaird, James Cockburn, Sean Gallagher, Anirban Choudhury, Alex Sirker, Peter Ludman, Mark de Belder, Samuel Copt, Mamas Mamas, Adam de Belder
AIMS: Access site choice for cases requiring rotational atherectomy (PCI-ROTA) is poorly defined. Using the British Cardiovascular Intervention Society PCI database, temporal changes and contemporary associates/outcomes of access site choice for PCI-ROTA were studied. METHODS AND RESULTS: Data were analysed from 11,444 PCI-ROTA procedures performed in England and Wales between 2007 and 2014. Multivariate logistic regression was used to identify predictors of access site choice and its association with outcomes...
April 2018: American Heart Journal
Patrice Cacoub, Pierre Nahon, Richard Layese, Lorraine Blaise, Anne Claire Desbois, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Ghassan Riachi, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capron, Gérard Thiefin, David Zucman, Vincent Di Martino, Corinne Isnard Bagnis, Marianne Ziol, Angela Sutton, Eric Letouze, Françoise Roudot-Thoraval, Etienne Audureau
BACKGROUND: The objective was to examine the role of a sustained virological response (SVR) on major adverse cardiovascular events (MACEs) in patients with compensated hepatitis C virus (HCV) cirrhosis. METHODS: Patients with the following criteria were enrolled in 35 French centers: (1) biopsy-proven HCV cirrhosis; (2) Child-Pugh A; (3) positive viremia; and (4) no prior liver complication, and then prospectively followed. All patients received HCV treatment after inclusion...
April 2018: American Heart Journal
Laurent Fauchier, Arnaud Bisson, Nicolas Clementy, Patrick Vourc'h, Denis Angoulvant, Dominique Babuty, Jean Michel Halimi, Gregory Y H Lip
BACKGROUND: Patients with kidney disease are more likely to develop atrial fibrillation (AF) than individuals with normal renal function, and more likely to suffer ischemic stroke (IS)/thromboembolism (TE). We investigated the relationship of kidney function evolution to IS/TE, mortality and bleeding in AF patients. METHODS: In a cohort of 8962 AF patients, 2653 had serum creatinine data, with 10894 patient-years of follow-up. Patients were stratified into quartiles of estimated glomerular filtration rate (eGFR) evolution (in mL/min per 1...
April 2018: American Heart Journal
Muath Bishawi, Brack Hattler, G Hossein Almassi, John A Spertus, Jacquelyn A Quin, Joseph F Collins, Frederick L Grover, Annie Laurie Shroyer
For advanced coronary disease, coronary artery bypass graft (CABG) surgery generally improves patients' symptoms and long-term survival. Unfortunately, some patients experience worse health-related quality of life (HRQL) after CABG. The objective of this study is to report the frequency and risk factors associated with 1-year post-CABG HRQL deterioration. METHODS: From 2002 to 2007, 2203 "Randomized On/Off Bypass" (ROOBY) trial patients randomly received either off-pump or on-pump CABG at 18 VA medical centers...
April 2018: American Heart Journal
Liefke C van der Heijden, Marlies M Kok, Paolo Zocca, Gillian A J Jessurun, Carl E Schotborgh, Ariel Roguin, Edouard Benit, Adel Aminian, Peter W Danse, Marije M Löwik, Gerard C M Linssen, Job van der Palen, Carine J M Doggen, Clemens von Birgelen
AIM: The aim was to compare in a noninferiority trial the efficacy and safety of 2 contemporary drug-eluting stents (DESs): a novel, durable polymer-coated stent versus an established bioabsorbable polymer-coated stent. METHODS AND RESULTS: The BIONYX trial ( is an investigator-initiated, prospective, randomized, patient- and assessor-blinded, international, multicenter study in all-comer patients with all types of clinical syndromes and lesions who require percutaneous coronary interventions with DES...
April 2018: American Heart Journal
Mahmoud Al Rifai, Philip Greenland, Michael J Blaha, Erin D Michos, Khurram Nasir, Michael D Miedema, Joseph Yeboah, Veit Sandfort, Alexis C Frazier-Wood, Steven Shea, Joao Ac Lima, Moyses Szklo, Wendy S Post, Roger S Blumenthal, John W McEvoy
BACKGROUND: Although cardiovascular disease (CVD) prevention traditionally emphasizes risk factor control, recent evidence also supports the promotion of "health factors" associated with cardiovascular wellness. However, whether such health factors exist among adults with advanced subclinical atherosclerosis is unknown. We aimed to study the association between health factors and events among persons with elevated coronary artery calcium (CAC). METHODS: Self-reported health-factors studied included nonsmoking, physical activity, Mediterranean-style diet, sleep quality, emotional support, low stress burden, and absence of depression...
April 2018: American Heart Journal
Ann Marie Navar, Michael J Pencina, Hillary Mulder, Pierre Elias, Eric D Peterson
BACKGROUND: Current cholesterol guidelines recommend using 10-year risk of atherosclerotic cardiovascular disease (ASCVD) to guide informed decisions regarding statin therapy, yet patients may have difficulty conceptualizing absolute risk estimates. Peer comparisons may provide an improved tool for patient risk comprehension. METHODS: Using data from the 2009-2014 National Health and Nutrition Examination Survey (NHANES), we estimated standardized risk percentiles for various age-, sex-, and race-specific subgroups based on their 10-year ASCVD risks using the Pooled Cohort Equations...
April 2018: American Heart Journal
Marcio Sommer Bittencourt
No abstract text is available yet for this article.
April 2018: American Heart Journal
Ziad Hijazi, Stefan H Hohnloser, Jonas Oldgren, Ulrika Andersson, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Paul A Reilly, Salim Yusuf, Lars Wallentin
No abstract text is available yet for this article.
April 2018: American Heart Journal
Kazuo Miyazawa, Daniele Pastori, Gregory Y H Lip
No abstract text is available yet for this article.
April 2018: American Heart Journal
Gordon Tomaselli, William H Roach, Ileana L Piña, Matthew E Oster, William H Dietz, Katie Horton, William B Borden, Kelly Brownell, Raymond J Gibbons, Jennifer J Otten, Christopher S Lee, Charles Hill, Paul A Heidenreich, David S Siscovick, Laurie P Whitsel
No abstract text is available yet for this article.
April 2018: American Heart Journal
Thomas O Bergmeijer, Jean-Luc Reny, Ruth E Pakyz, Li Gong, Joshua P Lewis, Eun-Young Kim, Daniel Aradi, Israel Fernandez-Cadenas, Richard B Horenstein, Ming Ta Michael Lee, Ryan M Whaley, Joan Montaner, Gian Franco Gensini, John H Cleator, Kiyuk Chang, Lene Holmvang, Willibald Hochholzer, Dan M Roden, Stefan Winter, Russ B Altman, Dimitrios Alexopoulos, Ho-Sook Kim, Jean-Pierre Déry, Meinrad Gawaz, Kevin Bliden, Marco Valgimigli, Rossella Marcucci, Gianluca Campo, Elke Schaeffeler, Nadia P Dridi, Ming-Shien Wen, Jae Gook Shin, Tabassome Simon, Pierre Fontana, Betti Giusti, Tobias Geisler, Michiaki Kubo, Dietmar Trenk, Jolanta M Siller-Matula, Jurriën M Ten Berg, Paul A Gurbel, Jean-Sebastien Hulot, Braxton D Mitchell, Matthias Schwab, Marylyn DeRiggi Ritchie, Teri E Klein, Alan R Shuldiner
RATIONALE: The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified...
April 2018: American Heart Journal
Eric J Velazquez, David A Morrow, Adam D DeVore, Andrew P Ambrosy, Carol I Duffy, Kevin McCague, Adrian F Hernandez, Ricardo A Rocha, Eugene Braunwald
OBJECTIVE: The objective is to assess the safety, tolerability, and efficacy of sacubitril/valsartan compared with enalapril in patients with heart failure (HF) with a reduced ejection fraction (EF) stabilized during hospitalization for acute decompensated HF. BACKGROUND: Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor, improves survival among ambulatory HF patients with a reduced EF. However, there is very limited experience with the in-hospital initiation of sacubitril/valsartan in patients who have been stabilized following hospitalization for acute decompensated HF...
April 2018: American Heart Journal
Louise Bowman, Marion Mafham, William Stevens, Richard Haynes, Theingi Aung, Fang Chen, Georgina Buck, Rory Collins, Jane Armitage
OBJECTIVES: The use of aspirin for the secondary prevention of cardiovascular disease (CVD) is firmly established, and the proportional reductions in heart attacks and strokes appear to be similar in people with and without diabetes. Uncertainty remains about the role of antiplatelet treatments for primary prevention of CVD, and guidelines vary in their recommendations. It has also been hypothesized that long-term aspirin can prevent gastro-intestinal and other cancers. Observational studies suggest associations between higher intakes of omega-3 fatty acids (FA) and lower rates of CVD, but there is no large-scale randomized evidence to support using prophylactic omega-3 FA supplementation in primary prevention...
April 2018: American Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"